As those watching the resource space are no doubt aware, the first six months of 2014 saw quite a few junior miners make forays into the medical marijuana sector.

Encouragingly for those companies, swathes of investors have been only too eager to follow. However, many analysts believe that’s a problem, in part because the sector is so new, but also because there’s still so much bureaucratic red tape and uncertainty surrounding marijuana use, even for medical purposes.


It’s thus unsurprising that “caution” and “profit” were the words of the hour at Monday’s Canadian Investor Conference marijuana panel, which featured activist Jodie Emery, Daniel Kiselbach of Deloitte Tax Law, Midas Letter’s James West and Paul Pelosi, Jr. of Verde Science (OTCMKTS:VRCI).

Why be cautious?

Giving his take on the need for caution, West explained that, at least in Canada, there’s a disconnect between what licensed commercial growers think they can achieve and what is actually achievable. Specifically, he said, those growers “predict that they will realize a price of $8 per gram” when “probably 25,000” of the 38,000 medical marijuana users registered with Health Canada “have been on disability and paying less than $1 a gram from compassionate growers and suppliers.”

While that could be a “great opportunit[y]” for traders able to ride stocks up as they’re buoyed by marijuana-related plans, it also means that ultimately there will be a “very slow and consistent degradation for the sector as a whole” as companies that don’t follow through on those plans disappear.

On a similar note, Emery pointed out that companies hoping to grow marijuana “are being promised a marketplace that … does exist,” but is already being served. In her opinion, it will thus be tough for companies to make the money they’ve been promised unless the market expands via “legalization for all” or unless they can “offer something that people can’t get elsewhere.”

Kiselbach was a little more positive, pointing to Tweed Marijuana’s (TSXV:TWD) success after listing on the TSX Venture Exchange and commenting, “there are opportunities, at least at this point in time, for making money.” However, he said, companies must do “careful planning in order to be profitable,” and unfortunately many are not making an effort to do so.

Profitable opportunities

Those comments may sound daunting, but none of the panelists denied that profiting from medical marijuana is indeed possible. Here’s what they said when asked which companies they think are “doing it right.”

  • West: “The best-looking business plan I’ve seen yet belongs to a company called THC Bank, which focuses on protecting and preserving the genetic integrity of various strains of marijuana for growers.”
  • Kiselbach: Kiselbach again identified Tweed as a company that is making money.
  • Emery: Though she noted that she wasn’t there to offer stock picks, Emery did point to her own success at working “in the marijuana industry without actually dealing with marijuana itself.” She also emphasized the importance of supporting companies that advocate for full legalization.
  • Pelosi: “Investors do flock to corporations which have strong corporate governance,” said Pelosi. Additionally, he noted that corporate mission is important, as is growth potential for revenue, a quality he believes Verde Science certainly has.

Certainly some food for thought for investors watching the sector.

Stay tuned for a video interview with Jodie Emery. 

 

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article. 

Related reading: 

Investing in Marijuana: A High-risk Green Rush

Making the Switch: 3 Junior Mining CEOs Explain the Pull of Medical Marijuana

Deloitte Tax Law: What to Look for in a Medical Marijuana Company

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less